PDS Biotechnology Corp Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PDS Biotechnology Corp stock issued during period, value, new issues for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, new issues for the quarter ending 2025-12-31 was $2.52M, a 20.47% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, new issues for the quarter ending 2025-06-30 was $50.00K.
- PDS Biotechnology Corp stock issued during period, value, new issues for the quarter ending 2025-03-31 was $6.92M, a 64.49% decline year-over-year.
- PDS Biotechnology Corp stock issued during period, value, new issues for fiscal 2023 was $16.10M, a 62.63% increase from fiscal 2022.
- PDS Biotechnology Corp stock issued during period, value, new issues for fiscal 2022 was $9.90M, a 79.61% decline from fiscal 2021.
- PDS Biotechnology Corp stock issued during period, value, new issues for fiscal 2021 was $48.54M, a 63.14% increase from fiscal 2020.
- PDS Biotechnology Corp stock issued during period, value, new issues for fiscal 2020 was $29.76M, a 3867.53% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $2.52M 10-K · filed 2026-03-30 | |
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $6.92M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $3.17M 10-K · filed 2025-03-27 | |
| 2024-03-31 | $19.49M 10-K · filed 2025-03-27 | $31.03M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $10.48M 10-K · filed 2025-03-27 | $16.10M 10-K · filed 2024-03-28 |
| 2023-09-30 | $815.20K 10-K · filed 2025-03-27 | $15.50M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | $243.74K 10-K · filed 2025-03-27 | $14.69M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | $4.59M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $9.86M 10-K · filed 2024-03-28 | $9.90M 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-08-08 | $48.54M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $48.54M 10-K · filed 2022-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | $48.54M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $29.76M 10-K · filed 2022-03-31 |
| 2020-09-30 | $17.79M 10-Q · filed 2020-11-13 | $29.76M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $11.97M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $11.97M 10-Q · filed 2021-05-13 | $12.00M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $750.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $1.25M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $25.24K 10-Q · filed 2020-08-13 | $1.53M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $750.00K 10-Q · filed 2020-05-13 | $1.54M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $475.90K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $1.55M 10-K · filed 2020-03-27 |
| 2018-09-30 | $275.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $44.00K 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $757.89K 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $17.38M 10-K · filed 2019-02-21 | |
| 2015-12-31 | $82.76M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |